Dong-SiTRichmanSWattjesMP. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol2014; 1(10): 755–764.
2.
McGuiganCCranerMGuadagnoJ.Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosurg Psychiatry2016; 87(2): 117–125.
BloomgrenGRichmanSHotermansC. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med2012; 366(20): 1870–1880.
5.
WattjesMPRoviraÀMillerD. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–Establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11(10): 597–606.
6.
Dong-SiTWeberTRichertN. Classification of natalizumab cases with progressive multifocal leukoencephalopathy. Neurology2012; 78: P07.058.
7.
BergerJRAksamitAJCliffordDB. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology2013; 80(15): 1430–1438.
8.
DahlhausSHoepnerRChanA. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry2013; 84: 1068–1074.
9.
HodelJOutteryckODubronC. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: Diagnostic precision with MR imaging. Radiology2016; 278(3): 863–872.
10.
WattjesMPWijburgMTVennegoorA. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Mult Scler2016; 22(9): 1174–1183.
11.
WijburgMTWitteBIVennegoorA.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry2016; 87(10): 1138–1145.
